Medtronic Announces Major Expansion in Galway, Ireland, Establishing European Software Development Center for Cardiac Implantable Devices

Instrument Family

Pioneer in Medical Device Media Reports

Share Professional Medical Device Knowledge

Source:Instrument Family,Reproduction without authorization is prohibited, and reproduction is allowed 24 hours later.

Recently, Medtronic announced a major expansion plan,Medtronic will add 85 new jobs at its existing facility in Galway, Ireland, and simultaneously establish a European Software Development Center.Focusing on the software technology development related to cardiac implantable devices, we help patients worldwide access higher-quality continuous medical services.

Focus on Cardiac Digitization

Expand and Build the European Innovation Hub

According to reports,This Galway expansion focuses on the construction of a European software development center, precisely targeting the digital upgrade needs of implantable cardiac devices.The position focuses on high-end fields such as software development, medical technical support, and data security. The scale of this position will continue to expand in the next three years.

The European Software Development Center will focus on "improving global patient outcomes" as its core objective.Focus on the development of cloud platforms and new interconnected software to achieve real-time communication between cardiac implant devices, the patient data they collect, and clinical physicians.

Through this "Continuously Connected Healthcare" model, healthcare professionals can more accurately monitor various heart conditions, while patients can gain greater confidence in their daily lives with the support of real-time medical monitoring, significantly improving clinical diagnosis and treatment efficiency.

Medtronic stated,This expansion relies on its existing industrial base in western Ireland, with the local pool of highly educated professionals providing critical support for the project's implementation.The establishment of this center is not only a core initiative for enterprises to deepen the research and development of new products, but also highly aligned with the national strategy promoted by the Industrial Development Authority (IDA) of Ireland to advance the digital healthcare industry.

The Industrial Development Agency of Ireland pointed out that the brand-new R&D center for patient care systems will further strengthen the deep integration of Ireland's technology industry with the medical technology sector. It will help the country leverage its technological advantages to continuously attract international investment, create high-quality jobs, and consolidate its competitiveness in the global digital healthcare field.

It is also reported that Medtronic will host a special event in Galway next week to provide a detailed interpretation of the long-term development benefits brought by this industrial integration.Currently, the recruitment for 85 new positions has officially started, covering various fields such as software development, medical technical support, and project management.

From Production Base to Global Strategic Hub

Deeply Rooted in Ireland for Over 40 Years

This Galway expansion is not accidental but a natural continuation of Medtronic's over four-decade-long commitment to Ireland, gradually establishing it as a global strategic hub. Medtronic’s presence in Ireland began in 1981 and, after more than forty years of dedication, has evolved from a single manufacturing plant into a core hub for global headquarters, R&D, and production. By 2025, Medtronic will have established five major sites across three locations in Ireland—Galway, Dublin, and Athlone—covering the entire chain of R&D, manufacturing, sales, and customer service.

Going back to 1981, Medtronic officially entered the Irish market, initially focusing on the production of basic medical devices. It established a European production base in Ireland by leveraging the local low costs and tax advantages. In 2014, Medtronic announced a $42.9 billion acquisition of Irish company Covidien.And completed the acquisition in 2015, relocating its global legal headquarters to Dublin, Ireland, marking the largest tax inversion merger in the history of the medical industry.。

AndGalway, as the core of Medtronic's layout in Ireland, has two major bases: Parkmore and Mervue.With over 2,000 employees, the Parkmore site serves as the global Center of Excellence for heart and vascular businesses, undertaking the R&D, production, and global operations of cardiac devices.

In 2015,Medtronic Builds New Factory in Galway to Produce IN.PACT Admiral Drug-Coated Balloon(DCB), used to treat peripheral artery disease, has become Medtronic's global sole DCB production base, relying on the local technical accumulation in the field of drug-device combination products to support global market supply.

It is worth mentioning that not long ago, MedtronicAnnounced plans to cease operations at its Santa Rosa, California plant and stated that the site'sRelated BusinessWill mainly relocate to Santa Ana, Minnesota, USA, and Galway, Ireland.。

Beyond production capacity and headquarters layout, Medtronic is deeply advancing the integration of industry, academia, and research in Ireland. In 2023, Medtronic signed a five-year cooperation agreement with the University of Galway, investing 5 million euros to jointly establish a medical device prototyping center.In February this year, the prototype center resulting from the cooperation between the two parties was officially launched, further strengthening Galway's position as the core of medical technology innovation in Europe.`, continuously providing Medtronic with R&D talent and technological achievements.`

The Unbreakable King of Cardiac Devices

Digitalization Becomes the Core Focus

Behind Ireland's expansion plan lies Medtronic's unshakable dominance in the cardiac device field, and its digital strategy is the key to solidifying its leading position and guiding the industry.

Cardiac devices serve as Medtronic's core growth engine,The latest released Q3 data for the fiscal year 2026 shows that the cardiovascular businessAn increase of 13.8% year-over-year,The most impressive performanceIts pacemakers, implantable defibrillators, and cardiac ablation products rank among the top tier globally. Supported by both traditional device barriers and digital ecosystem layouts, its core products continue to iterate, leading the industry in digital transformation.

From the perspective of cardiovascular business, inIn terms of cardiac rhythm management devices, it is the absolute global leader in cardiac pacemakers, with core products including wireless lead pacemakers (Micra), cardiac resynchronization therapy (CRT) devices, and implantable cardioverter-defibrillators (ICD), among others. Among them,Micra, as the world's smallest leadless pacemaker, has a volume only 1/10 that of traditional products. Its design, which eliminates the need for implantable leads, significantly reduces the risk of infection and has gained widespread adoption globally.

At the same time, itsCardiac Ablation SolutionsKnown as the "aircraft carrier" in the field of electrophysiology,Affera 3D Electrophysiology Navigation and Pulsed RF Ablation System, Sphere-9 Pulsed RF Ablation CatheterCore products such as these can complete the entire process of cardiac lesion mapping and ablation therapy. In the third quarter of the 2026 fiscal year, revenue from this business surged by 80%, with the growth rate in the U.S. market reaching an impressive 137%, making it one of the fastest-growing segments of the company.

InField of Structural Heart Disease, Evolut FX+ Transcatheter Aortic Valve System, Zero-Metal Artificial Heart Valve Avalus and other products, fully cover scenarios such as aortic valve replacement and heart failure treatment.

And inDevice Connectivity, Data-Driven, AI EmpowermentAt the Core of Digital Transformation,In the future, Medtronic's Galway European Software Center will serve as a key carrier, focusing on three major dimensions: device intelligence, cloud platform construction, and AI clinical applications.Achieve real-time data collection, security analysis, and risk warning to enhance the precision of diagnosis and treatment.

——

Currently, the competition in the global medical device industry has shifted from单一产品比拼toEcological CompetitionDigital capabilities, global layout, and industry-academia-research collaboration have become core competencies. Medtronic's strategic expansion in Ireland is not only a crucial step in deepening its presence in the global market and solidifying its leading position in the cardiac device field, but also a vivid example of the integration of digitalization and globalization within the industry.

So, in the future, with the establishment of Galway European Software Center, how will Medtronic...Further strengthen its leading advantage in the field of digital diagnosis and treatment of heart disease, and provide more efficient, accurate and accessible medical services for patients worldwide? Instrument Family will continue to pay attention.